Article
Reproductive Biology
Zhen Yuan, Ying Zhang, Dongyan Cao, Keng Shen, Qingshui Li, Guonan Zhang, Xiaohua Wu, Manhua Cui, Ying Yue, Wenjun Cheng, Li Wang, Pengpeng Qu, Guangshi Tao, Jianqing Hou, Lixin Sun, Yuanguang Meng, Guiling Li, Changzhong Li, Huirong Shi, Yaqing Chen
Summary: This study evaluated the efficacy and safety of PLD in treating platinum-resistant and platinum-refractory relapse in patients with epithelial ovarian, fallopian tube, and peritoneal cancer. The results showed that PLD was associated with satisfactory efficacy, low frequency of adverse events, and high patient quality of life, with low baseline CA125 levels and a reduction in CA125 after the first cycle predicting satisfactory efficacy.
JOURNAL OF OVARIAN RESEARCH
(2021)
Article
Oncology
Sandro Pignata, Giovanni Scambia, Alessandro Villanucci, Emanuele Naglieri, Mikel Arruti Ibarbia, Federica Brusa, Hugues Bourgeois, Roberto Sorio, Antonio Casado, Dietmar Reichert, Catherine Dopchie, Beatriz De Rivas, Luis Miguel de Sande
Summary: The study showed that the combination of trabectedin/PLD is a clinically meaningful and safe option for patients with platinum-sensitive recurrent ovarian cancer, regardless of prior treatment with an antiangiogenic drug. Patients overall had good survival outcomes and clinical benefits.
Article
Oncology
Takuma Ooyama, Yuko Shimoji, Tadaharu Nakasone, Yoshihisa Arakaki, Yusuke Taira, Tomoko Nakamoto, Wataru Kudaka, Yoichi Aoki
Summary: Pegylated liposomal doxorubicin (PLD) has a high disease control rate (DCR) in the treatment of recurrent ovarian cancer, and the treatment effect can be predicted by the reduction of CA125 level after 2 courses.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Katherine C. Fuh, Michael A. Bookman, Joyce F. Liu, Robert L. Coleman, Thomas J. Herzog, Premal H. Thaker, Bradley J. Monk, Randy Anderson, Gail McIntyre, Reshma Rangwala, Kathleen N. Moore
Summary: AVB-500, a novel high affinity Fc-sAXL fusion protein, combined with chemotherapy showed promising clinical activity in platinum-resistant ovarian cancer (PROC) patients, with no dose limiting toxicities observed.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Reproductive Biology
Xin-Ru Li, Yi Zhu, Guo-Nan Zhang, Jian-Ming Huang, Li-Xia Pei
Summary: This study found through meta-analysis that in recurrent ovarian cancer, pegylated liposomal doxorubicin plus carboplatin was more effective than paclitaxel plus carboplatin, while pegylated liposomal doxorubicin monotherapy showed similar survival outcomes to other monotherapies. Both treatment regimens were well tolerated in terms of side effects.
JOURNAL OF OVARIAN RESEARCH
(2021)
Article
Oncology
J. A. Perez-Fidalgo, A. Cortes, E. Guerra, Y. Garcia, M. Iglesias, U. Bohn Sarmiento, E. Calvo Garcia, L. Manso Sanchez, A. Santaballa, A. Oaknin, A. Redondo, M. J. Rubio, A. Gonzalez-Martin
Summary: The study investigated the efficacy of a combination of DNA-damaging chemotherapy and olaparib in platinum-resistant ovarian cancer (PROC) patients, showing significant activity in PROC regardless of BRCA status. PLD30 was better tolerated with less adverse events compared to PLD40 in the combination therapy.
Review
Reproductive Biology
Xin-Ru Li, Xing-Han Cheng, Guo-Nan Zhang, Xiao-Xin Wang, Jian-Ming Huang
Summary: This study summarizes the high-risk factors, clinical dose thresholds, and cardiac function testing modalities for PLD-induced cardiotoxicity, providing guidance for its clinical use.
JOURNAL OF OVARIAN RESEARCH
(2022)
Article
Immunology
Shirin Hekmatirad, Milad Moloudizargari, Ali Akbar Moghadamnia, Sohrab Kazemi, Mousa Mohammadnia-Afrouzi, Maryam Baeeri, Fatemeh Moradkhani, Mohammad Hossein Asghari
Summary: Inhibition of exosome release can reduce drug resistance in cancer cells, making them more vulnerable to the cytotoxic effects of chemotherapy drugs. This study specifically looked at the effects of exosome release inhibition on the resistance of U937 cells to PEGylated liposomal doxorubicin (PLD). Exosome inhibitors could potentially reduce the concentration of chemotherapy drugs needed and minimize associated side effects.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Paul H. Sugarbaker, O. Anthony Stuart
Summary: The study revealed that the retention rate of nanoparticle PLD within peritoneal tissues is low, making it unsuitable for HIPEC. Early postoperative intraperitoneal chemotherapy (EPIC) at normothermic conditions is preferred for drug administration.
Article
Oncology
Hiroyuki Yoshida, Keiichi Fujiwara
Summary: This study evaluated the relationship between adipose tissue status and the efficacy of PLD. It was found that patients with a high visceral to subcutaneous adipose tissue area ratio (VSR) had a poor response to PLD and shorter progression-free survival (PFS). Thus, VSR is an important predictive biomarker for the efficacy of PLD.
Article
Pharmacology & Pharmacy
Maryam Ebrahimi Nik, Mahmoud Reza Jaafari, Mohammad Mashreghi, Sara Nikoofal-Sahlabadi, Mohamadreza Amin, Hamid Reza Sadeghnia, Mehrdad Iranshahi, Jamshid Gholizadeh Navashenaq, Bizhan Malaekeh-Nikouei
Summary: The study developed new liposomal formulations to enhance the anti-cancer therapeutic application of Galbanic acid, and demonstrated that RGD peptide decoration could improve targeted delivery to tumor vasculature. The results showed that the targeted liposomes could enhance receptor-mediated endocytosis both in vitro and in vivo, leading to increased accumulation in colon tumors.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Oncology
Katsuhiko Nara, Ayumi Taguchi, Takehito Yamamoto, Tetsushi Tsuruga, Yuri Tojima, Yuichiro Miyamoto, Michihiro Tanikawa, Kenbun Sone, Mayuyo Mori, Tappei Takada, Hiroshi Suzuki, Yutaka Osuga
Summary: The study aimed to retrospectively assess the primary preventive effect of a combination of regional cooling and oral dexamethasone therapy on hand-foot syndrome (HFS) induced by pegylated liposomal doxorubicin (PLD) in ovarian cancer patients. The results demonstrated the efficacy of regional cooling and oral dexamethasone therapy for primary prevention of PLD-induced HFS in ovarian cancer patients.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Jiaqiang Wang, Fan Zhang, Shuping Dong, Yang Yang, Fangfang Gao, Guancong Liu, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian
Summary: The efficacy and safety of apatinib plus doxorubicin and cisplatin as neoadjuvant therapy for osteosarcoma have been preliminarily validated, but further clinical trials are needed to confirm its effectiveness.
FRONTIERS IN ONCOLOGY
(2023)
Article
Obstetrics & Gynecology
Hailei Yang, Aizhi Geng, Zhenfeng Wang, Chuanzhong Wu
Summary: This study aimed to explore the efficacy and safety of apatinib plus chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC). The results showed that apatinib plus chemotherapy increased objective response rate, disease control rate, progression-free survival, and overall survival compared to chemotherapy alone.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Aizhi Geng, Hailei Yang, Zhenfeng Wang, Chuanzhong Wu
Summary: This study found that apatinib plus paclitaxel has better efficacy and acceptable toxicity compared to paclitaxel monotherapy in platinum-resistant recurrent ovarian cancer patients.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Zhao Xu, Xiaobing Wang, Yue Dai, Lingyi Kong, Fengyun Wang, Huan Xu, Dan Lu, Jie Song, Zhiguo Hou
CHEMICO-BIOLOGICAL INTERACTIONS
(2010)
Article
Biochemical Research Methods
Zhiguo Hou, Jianguang Luo, Lingyi Kong
Article
Biochemical Research Methods
Zhiguo Hou, Deran Xu, Shun Yao, Jianguang Luo, Lingyi Kong
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
(2009)
Article
Engineering, Chemical
Zhiguo Hou, Jianguang Luo, Junsong Wang, Lingyi Kong
SEPARATION AND PURIFICATION TECHNOLOGY
(2010)
Article
Oncology
Yansong Lin, Shukui Qin, Zhiyong Li, Hui Yang, Wei Fu, Shaohua Li, Wenxin Chen, Zairong Gao, Weibing Miao, Huiqin Xu, Qing Zhang, Xinming Zhao, Jiandong Bao, Linfa Li, Yuan Ren, Chenghe Lin, Shanghua Jing, Qingjie Ma, Jun Liang, Guang Chen, Hong Zhang, Yifan Zhang, Xianfeng Zhou, Yaxiong Sang, Zhiguo Hou
Summary: The study aimed to assess the efficacy and safety of apatinib in patients with progressive locally advanced or metastatic RAIR-DTC. Results showed that apatinib demonstrated significant clinical benefits in terms of prolonged PFS and improved overall survival with manageable safety profile.
Article
Gastroenterology & Hepatology
Xiangrui Meng, Tao Wu, Yonggui Hong, Qingxia Fan, Zhonghai Ren, Yanzhen Guo, Xiuli Yang, Pei Shi, Jiamei Yang, Xianzhe Yin, Zhiquan Luo, Jin Xia, Yue Zhou, Mengli Xu, Enjie Liu, Guozhong Jiang, Shenglei Li, Feng Zhao, Chi Ma, Chuanxiang Ma, Zhiguo Hou, Jing Li, Junsheng Wang, Feng Wang
Summary: This study assessed the combination of Camrelizumab and Apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma and demonstrated promising efficacy and manageable toxicity.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Multidisciplinary Sciences
Zhaoqing Tang, Yan Wang, Dan Liu, Xuefei Wang, Chen Xu, Yiyi Yu, Yuehong Cui, Cheng Tang, Qian Li, Jing Sun, Qian Zhang, Yuan Ji, Guifen Ma, Haojie Li, Zhenbin Shen, Kuntang Shen, Rongrong Zheng, Zhiguo Hou, Tianshu Liu, Jiping Wang, Yihong Sun
Summary: Neoadjuvant camrelizumab plus concurrent chemoradiotherapy shows promising pathological response in patients with locally advanced gastric adenocarcinoma, with an acceptable safety profile.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, General & Internal
Jin Li, Shukui Qin, Lu Wen, Junsheng Wang, Wenying Deng, Weijian Guo, Tongfu Jia, Da Jiang, Guifang Zhang, Yifu He, Yi Ba, Haijun Zhong, Lin Wang, Xiaoyan Lin, Jianwei Yang, Jun Zhao, Yuxian Bai, Xiangyuan Wu, Feng Gao, Guogui Sun, Yongjuan Wu, Feng Ye, Qiong Wang, Zhong Xie, Tienan Yi, Yong Huang, Guohua Yu, Lin Lu, Ying Yuan, Wei Li, Likun Liu, Yuping Sun, Ying Sun, Lifeng Yin, Zhiguo Hou
Summary: The AHEAD study aimed to verify the safety and efficacy of apatinib in patients with advanced gastric cancer in clinical practice settings. The study confirmed the acceptable safety profile and clinical benefit of apatinib as a third- or later-line treatment for advanced gastric cancer.